At A CAGR Of 35.42% , Global Alpha-1 Antitrypsin Drugs Industry will rise in the period of 2016-2020

ResearchMoz presents this most up-to-date research on Global Alpha-1 Antitrypsin Drugs Market 2016-2020.

About Alpha-1 antitrypsin Drugs

Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein produced in the liver that helps in the inactivation of enzymes such as elastase, which break down proteins during inflammation induced by some injury. The decline in alpha-1 antitrypsin levels in the blood results in a rare genetic condition known as alpha-1 antitrypsin deficiency (AATD), which leads to the development of respiratory and liver diseases, and severe skin infections. The disease is passed on from parents to an offspring through mutated genes. Augmentation therapy using drugs derived from human plasma helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the condition.

Technavios analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR of 35.42% during the period 2016-2020.

Covered :
The report covers the present scenario and the growth prospects of the global alpha-1 antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded drugs and off-label drugs used for the symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other disorders.

Segments based on geography:

To Get Sample Copy of Report visit @

Technavio’s report, Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Baxter International
CSL Behring

Other prominent vendors
Abeona Therapeutics
Alnylam Pharmaceuticals
Applied Genetic Technologies
Arrowhead Research
Laboratoire franais du Fractionnement et des Biotechnologies
ProMetic Life Sciences

Key driver
Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)
For a full, detailed list, view our report

Key challenge
Limited plasma fractionation capacity
For a full, detailed list, view our report

Key trend
Increasing awareness about therapy
For a full, detailed list, view our report

For More Information Kindly Contact:

Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Follow us on LinkedIn @

%d bloggers like this: